Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

The neurotransmitter dopamine is a key factor in central nervous system (CNS) function,
regulating many processes including reward, movement, and cognition. Dopamine also …

The neurodevelopmental and dopamine hypotheses are leading theories of the
pathoetiology of schizophrenia, but they were developed in isolation. However, since they …

The synaptic hypothesis of schizophrenia has been highly influential. However, new
approaches mean there has been a step-change in the evidence available, and some tenets …

Dopamine receptors are widely distributed within the brain where they play critical
modulator roles on motor functions, motivation and drive, as well as cognition. The …

Timely screening of neuromyelitis optica spectrum disorder (NMOSD) and differential
diagnosis from myelin oligodendrocyte glycoprotein associated disorder (MOGAD) are the …

The idea that a longer duration of untreated psychosis (DUP) leads to poorer outcomes has
contributed to extensive changes in mental health services worldwide and has attracted …

Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …

Schizophrenia has been an evolutionary paradox: it has high heritability, but it is associated
with decreased reproductive success. The causal genetic variants underlying schizophrenia …

Modern interest in muscarinic acetylcholine receptor (mAChR) activators for schizophrenia
began in the 1990s when xanomeline, an M 1/M 4-preferring mAChR agonist developed for …